tirzepatide type 1 diabetes trial Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with 2 (SURPASS-1): a double-blind, randomised, phase 3 Tirzepatide cuts risk of diabetes

This is not to say it is a wonder drug, though, as the National Library of Medicine notes, it has been known to cause tumors in lab animals, but it remains unclear if it causes a higher risk in humans

CAR T cells of LTR show high immunometabolic polyfunctionality post-infusion supported by the bone marrow (BM) microenvironment To study the relationship between immunometabolism and CAR T cell anti-tumor activity in patients, we examined day 28 post-infusion BM samples (Fig

Safety data in humans is not as robust as it is for FDA approved medications

Drug-specific phosphorylation signatures began to appear between 5 and 30 min after exposure, the magnitude of these changes differing between treatments (Fig

A.JaeschkeH.MarenziG.RicheldiL.et al